Mario Ramos - 02 Mar 2026 Form 4 Insider Report for Evolent Health, Inc. (EVH)

Role: Chief Financial Officer
Signature: /s/ Jonathan Weinberg, Attorney-in-fact
Issuer symbol: EVH
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2026, 17:43:43 UTC
Previous filing: 05 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ramos Mario	Chief Financial Officer	C/O EVOLENT HEALTH, INC., 1812 N. MOORE ST., STE. 1705, ARLINGTON	/s/ Jonathan Weinberg, Attorney-in-fact	04 Mar 2026	0001891060

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVH	Performance-Based Share Unit	Award		+429,041		$0.000000^*	429,041	02 Mar 2026	Class A Common Stock	429,041		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents performance-based share units (PSUs) granted to Mr. Ramos pursuant to the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan. The PSUs may be earned based on the achievement of certain stock price performance conditions from March 1, 2027 to February 28, 2029, subject to satisfying certain service-based conditions. Each PSU is shown at the target level, and the actual amount earned after completion of the performance period may range from 0% to 250% of the target level.

Content

Represents performance-based share units (PSUs) granted to Mr. Ramos pursuant to the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan. The PSUs may be earned based on the achievement of certain stock price performance conditions from March 1, 2027 to February 28, 2029, subject to satisfying certain service-based conditions. Each PSU is shown at the target level, and the actual amount earned after completion of the performance period may range from 0% to 250% of the target level.